核医学診断装置（PET、SPECT）の世界市場...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 15
1.2 List of Figures 19

2 Introduction 21
2.1 Catalyst 21
2.2 Related Reports 22

3 Industry Overview 23
3.1 Nuclear Imaging Techniques 23
3.1.1 Positron Emission Tomography 23
3.1.2 Single-Photon Emission Computed Tomography 25
3.1.3 Planar Scintigraphy 25
3.1.4 Hybrid Imaging 26
3.2 Clinical Applications of Nuclear Imaging Technology 31
3.2.1 Cancer 31
3.2.2 Cardiology 33
3.2.3 Neurology 35
3.2.4 Infection and Inflammation 37
3.3 Advantages and Disadvantages of Nuclear Imaging Technologies 40
3.4 Market Access 41
3.4.1 Product Life Cycle 41
3.4.2 Purchasing Decisions 43
3.4.3 Equipment Leasing 49
3.4.4 Replacement of PET/CT by PET/MRI 49
3.5 Reimbursement 54
3.5.1 Overview 54
3.5.2 US 55
3.5.3 France 55
3.5.4 Germany 57
3.5.5 Italy 58
3.5.6 Spain 59
3.5.7 UK 60
3.5.8 Japan 61
3.5.9 Brazil 61
3.5.10 China 62
3.5.11 India 63
3.6 Procedure Trends 64
3.6.1 US 64
3.6.2 France 67
3.6.3 Germany 69
3.6.4 Italy 72
3.6.5 Spain 74
3.6.6 UK 76
3.6.7 Japan 79
3.6.8 Brazil 81
3.6.9 China 84
3.6.10 India 86
3.7 Regulatory Issues/Recalls 89
3.8 M&As and Key Partnerships 90
3.9 Economic Impact 92
3.9.1 US 92
3.9.2 Europe 95

4 Unmet Needs 96
4.1 Overview 96
4.2 Improved Reimbursement for New Techniques 96
4.3 Lack of Binding Clinical Guidelines 100
4.4 Patient Comfort and Convenience 100
4.5 Reducing Radiation Exposure 101
4.6 Improved Scanner Performance 103
4.7 Image Processing Software Improvements 104
4.8 Increased Risk of Artifacts in Hybrid Images 106
4.9 Demand for New Radiotracers 107
4.10 Improved Clinical Input into the Design Process 109

5 Market Opportunity Analysis 110
5.1 Cheaper, Simpler Nuclear Imaging Devices 110
5.2 SPECT/CT in Developing Countries 110
5.3 Increased Demand for Teleradiology Services 113

6 Market Drivers and Barriers 115
6.1 Driver: Aging Population and Increasing Disease Prevalence 115
6.2 Driver: Referring Physician Awareness 116
6.3 Driver: Defensive medicine 117
6.4 Driver: Patient Awareness 119
6.5 Driver: Self-Referral 119
6.6 Driver: New Imaging Agents 120
6.7 Driver: Increasing Demand for Cancer Diagnostic Tests 120
6.8 Driver: Companion Diagnostic Testing 121
6.9 Barrier: Comparative Effectiveness Research 122
6.10 Barrier: Reimbursement Legislation 124
6.11 Barrier: Increasing Demand for Nuclear Imaging in Developing Markets 124
6.12 Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging 126
6.13 Barrier: Greater Payer Scrutiny of EMRs 126
6.14 Barrier: Increased Use of Appropriateness Criteria 127
6.15 Barrier: Practice Guidelines to Reduce Unnecessary Procedures 129
6.16 Barrier: Imaging Facility Accreditation 129
6.17 Barrier: Loss of Nuclear Medicine Skills 130
6.18 Barrier: High Cost of Instruments and Reagents 131
6.19 Barrier: Radiopharmaceutical Cost and Supply Difficulties 132
6.20 Barrier: Medical Device Excise Tax 135
6.21 Barrier: Hospital Consolidation 135

7 Competitive Assessment 137
7.1 Overview 137
7.2 Dedicated PET Systems 137
7.2.1 Overview 137
7.2.2 Product Profile 138
7.2.3 SWOT Analysis 139
7.3 PET/CT Systems 139
7.3.1 Overview 139
7.3.2 Product Profiles 140
7.3.3 SWOT Analysis 142
7.4 PET/MRI Systems 142
7.4.1 Overview 142
7.4.2 Product Profile 144
7.4.3 SWOT Analysis 145
7.5 Dedicated SPECT Systems 145
7.5.1 Overview 145
7.5.2 Product Profile 147
7.5.3 SWOT Analysis 148
7.6 SPECT/CT Systems 149
7.6.1 Overview 149
7.6.2 Product Profile 151
7.6.3 SWOT Analysis 152
7.7 PET/Ultrasound and SPECT/Ultrasound Systems 153
7.7.1 Overview 153
7.7.2 Product Profile 153
7.7.3 SWOT Analysis 154

8 Pipeline Assessment 155
8.1 Overview 155
8.2 Pipeline by Phases in Development 156
8.3 Product Profiles 156
8.3.1 Brain Biosciences CerePET 156
8.3.2 ECORAD Dual Modality Imager 158
8.3.3 FMI Technologies ScintiStar PET/CT 159
8.3.4 IntraMedical Imaging Marginator Beta Camera 161
8.3.5 INSERT SPECT/MRI 162
8.3.6 Nucare/Zecotek Photonics New Generation PET Scanning Device 165
8.3.7 Philips Healthcare PET Alpha Ring Detector 166
8.3.8 Photo Diagnostic Systems NeuroPET/CT 167
8.3.9 SynchroPET Breast PET/MRI 168
8.3.10 SynchroPET Wrist Scanner 169
8.3.11 SurgicEye SPECT Hybrid 170

9 Clinical Trials to Watch 172
9.1 Overview 172
9.2 Clinical Trial Profiles 172

10 Current and Future Players 175
10.1 Overview 175
10.2 Trends in Corporate Strategy 175
10.3 Company Profiles 176
10.3.1 DDD-Diagnostic 176
10.3.2 Digirad 178
10.3.3 GE Healthcare 182
10.3.4 GVI Medical Devices 187
10.3.5 Mediso Medical Imaging Systems 189
10.3.6 NeuroLogica 191
10.3.7 Neusoft Medical Systems 194
10.3.8 NuCare Medical Systems 197
10.3.9 Oncovision 199
10.3.10 Philips Healthcare 201
10.3.11 Shimadzu 208
10.3.12 Siemens Healthcare 213
10.3.13 SurgicEye 219
10.3.14 Toshiba Medical 222
10.3.15 Other Companies 227

11 Market Outlooks 230
11.1 Company Market Share Analysis 230
11.1.1 Global Overview 230
11.1.2 US 231
11.1.3 France 231
11.1.4 Germany 232
11.1.5 Italy 233
11.1.6 Spain 234
11.1.7 UK 235
11.1.8 Japan 236
11.1.9 Brazil 237
11.1.10 China 238
11.1.11 India 239
11.2 Market Segment Share 240
11.2.1 SPECT & SPECT/CT 240
11.2.2 PET, PET/CT & PET/MRI 241
11.3 By Geography 243
11.3.1 Global Overview 243
11.3.2 US 246
11.3.3 France 248
11.3.4 Germany 250
11.3.5 Italy 252
11.3.6 Spain 255
11.3.7 UK 257
11.3.8 Japan 259
11.3.9 Brazil 262
11.3.10 China 265
11.3.11 India 268

12 Appendix 271
12.1 Abbreviations 271
12.2 Bibliography 276
12.3 Methodology 307
12.3.1 Overview 307
12.3.2 Coverage 307
12.3.3 Secondary Research 307
12.4 Physicians and Specialists Included in This Study 309
12.5 Primary Research 311
12.5.1 Primary Research – Key Opinion Leader Interviews 311
12.5.2 Expert Panel Validation 311
12.5.3 Stakeholder Survey 312
12.6 Forecasting Methodology 314
12.7 About the Authors 315
12.7.1 Andrew Thompson, PhD, Senior Analyst 315
12.7.2 Priya Radhakrishnan, MBA, Director, Medical Devices 315
12.7.3 Bonnie Bain, PhD, Global Head of Healthcare 316
12.8 About GlobalData 317
12.9 Disclaimer 317